FDA Puts Cancer Drug Approval on Hold
The FDA delays a decision on Exelixis' new cancer treatment for colorectal cancer, impacting patients and the company.
Patients waiting for new cancer treatments face another delay. The FDA paused its decision on a new drug from Exelixis. This drug, a kinase inhibitor, aims to fight advanced colorectal cancer.
The drug combines with Roche's Tecentriq. Doctors hope it can help people whose cancer has spread. This delay means patients must wait longer for a potential new option.
Exelixis develops new medicines. This specific drug targets advanced colorectal cancer. The company now works with the FDA to answer more questions.
This news affects Exelixis' plans. It also impacts the many patients who look for better ways to treat this serious disease. We will watch for the FDA's next steps.
Source: FierceBiotech
More from Biotech
